tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells. 2013

Sergio Valente, and Daniela Trisciuoglio, and Maria Tardugno, and Rosaria Benedetti, and Donatella Labella, and Daniela Secci, and Ciro Mercurio, and Roberto Boggio, and Stefano Tomassi, and Salvatore Di Maro, and Ettore Novellino, and Lucia Altucci, and Donatella Del Bufalo, and Antonello Mai, and Sandro Cosconati
Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, P.le A. Moro 5, 00185 Roma, Italy.

Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-α-tubulin levels in human acute myeloid leukemia U937 cells. In the same cell line, compounds 8 b and 10 c elicited 18.4 and 21.4 % apoptosis, respectively (SAHA: 16.9 %), and the pyrrole anilide 9 c displayed the highest cytodifferentiating effect (90.9 %). In tests against a wide range of various cancer cell lines to determine its antiproliferative effects, compound 10 c exhibited growth inhibition from sub-micromolar (neuroblastoma LAN-5 and SH-SY5Y cells, chronic myeloid leukemia K562 cells) to low-micromolar (lung H1299 and A549, colon HCT116 and HT29 cancer cells) concentrations. In HT29 cells, 10 c increased histone H3 acetylation, and decreased the colony-forming potential of the cancer cells by up to 60 %.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012097 Repressor Proteins Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release. Repressor Molecules,Transcriptional Silencing Factors,Proteins, Repressor,Silencing Factors, Transcriptional
D002219 Carbamates Derivatives of carbamic acid, H2NC( Carbamate,Aminoformic Acids,Carbamic Acids,Acids, Aminoformic,Acids, Carbamic
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006655 Histone Deacetylases Deacetylases that remove N-acetyl groups from amino side chains of the amino acids of HISTONES. The enzyme family can be divided into at least three structurally-defined subclasses. Class I and class II deacetylases utilize a zinc-dependent mechanism. The sirtuin histone deacetylases belong to class III and are NAD-dependent enzymes. Class I Histone Deacetylases,Class II Histone Deacetylases,HDAC Proteins,Histone Deacetylase,Histone Deacetylase Complexes,Complexes, Histone Deacetylase,Deacetylase Complexes, Histone,Deacetylase, Histone,Deacetylases, Histone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Sergio Valente, and Daniela Trisciuoglio, and Maria Tardugno, and Rosaria Benedetti, and Donatella Labella, and Daniela Secci, and Ciro Mercurio, and Roberto Boggio, and Stefano Tomassi, and Salvatore Di Maro, and Ettore Novellino, and Lucia Altucci, and Donatella Del Bufalo, and Antonello Mai, and Sandro Cosconati
January 2007, The international journal of biochemistry & cell biology,
Sergio Valente, and Daniela Trisciuoglio, and Maria Tardugno, and Rosaria Benedetti, and Donatella Labella, and Daniela Secci, and Ciro Mercurio, and Roberto Boggio, and Stefano Tomassi, and Salvatore Di Maro, and Ettore Novellino, and Lucia Altucci, and Donatella Del Bufalo, and Antonello Mai, and Sandro Cosconati
February 2006, Human cell,
Sergio Valente, and Daniela Trisciuoglio, and Maria Tardugno, and Rosaria Benedetti, and Donatella Labella, and Daniela Secci, and Ciro Mercurio, and Roberto Boggio, and Stefano Tomassi, and Salvatore Di Maro, and Ettore Novellino, and Lucia Altucci, and Donatella Del Bufalo, and Antonello Mai, and Sandro Cosconati
December 2004, Cancer,
Sergio Valente, and Daniela Trisciuoglio, and Maria Tardugno, and Rosaria Benedetti, and Donatella Labella, and Daniela Secci, and Ciro Mercurio, and Roberto Boggio, and Stefano Tomassi, and Salvatore Di Maro, and Ettore Novellino, and Lucia Altucci, and Donatella Del Bufalo, and Antonello Mai, and Sandro Cosconati
February 2005, The Prostate,
Sergio Valente, and Daniela Trisciuoglio, and Maria Tardugno, and Rosaria Benedetti, and Donatella Labella, and Daniela Secci, and Ciro Mercurio, and Roberto Boggio, and Stefano Tomassi, and Salvatore Di Maro, and Ettore Novellino, and Lucia Altucci, and Donatella Del Bufalo, and Antonello Mai, and Sandro Cosconati
November 2010, ACS medicinal chemistry letters,
Sergio Valente, and Daniela Trisciuoglio, and Maria Tardugno, and Rosaria Benedetti, and Donatella Labella, and Daniela Secci, and Ciro Mercurio, and Roberto Boggio, and Stefano Tomassi, and Salvatore Di Maro, and Ettore Novellino, and Lucia Altucci, and Donatella Del Bufalo, and Antonello Mai, and Sandro Cosconati
April 2011, ChemMedChem,
Sergio Valente, and Daniela Trisciuoglio, and Maria Tardugno, and Rosaria Benedetti, and Donatella Labella, and Daniela Secci, and Ciro Mercurio, and Roberto Boggio, and Stefano Tomassi, and Salvatore Di Maro, and Ettore Novellino, and Lucia Altucci, and Donatella Del Bufalo, and Antonello Mai, and Sandro Cosconati
May 2019, Cancers,
Sergio Valente, and Daniela Trisciuoglio, and Maria Tardugno, and Rosaria Benedetti, and Donatella Labella, and Daniela Secci, and Ciro Mercurio, and Roberto Boggio, and Stefano Tomassi, and Salvatore Di Maro, and Ettore Novellino, and Lucia Altucci, and Donatella Del Bufalo, and Antonello Mai, and Sandro Cosconati
February 2023, European journal of medicinal chemistry,
Sergio Valente, and Daniela Trisciuoglio, and Maria Tardugno, and Rosaria Benedetti, and Donatella Labella, and Daniela Secci, and Ciro Mercurio, and Roberto Boggio, and Stefano Tomassi, and Salvatore Di Maro, and Ettore Novellino, and Lucia Altucci, and Donatella Del Bufalo, and Antonello Mai, and Sandro Cosconati
May 2003, International journal of cancer,
Sergio Valente, and Daniela Trisciuoglio, and Maria Tardugno, and Rosaria Benedetti, and Donatella Labella, and Daniela Secci, and Ciro Mercurio, and Roberto Boggio, and Stefano Tomassi, and Salvatore Di Maro, and Ettore Novellino, and Lucia Altucci, and Donatella Del Bufalo, and Antonello Mai, and Sandro Cosconati
January 2007, Current medicinal chemistry,
Copied contents to your clipboard!